Related Articles
Research
BTIG Downgrades Aardvark Therapeutics to Neutral From Buy
Aardvark Therapeutics (AARD) has an average rating of overweight and mean price target of $18.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$AARD
Research
AtkinsRealis Group Price Target Lowered to $117 at TD
TD Securities lowered its price target on AtkinsRealis Group Inc. (ATRL.TO) to $117 from $127 on Friday.Analyst Michael Tupholme maintained a Buy rating on shares of the Canadian engineering services and nuclear company following its Q1 results."We see an H2/26 nuclear tech. decision in Ontario as a re-rating catalyst," Tupholme said in a note to clients."Also, we believe the 2026 Nuclear revenue guide could be conservative, given Q1/26 growth of +37% y/y vs. vs. FY2026 guide of +9% y/y," the analyst said. "ESR org. growth is strong and FY2026 ESR margin expansion remains intact."Tupholme said the price target reduction is due to a "reduced ESR target multiple of 11.0x (was 12.5x), reflecting lower sector valuations."
$ATRL.TO
Research
Wedbush Initiates Solventum at Outperform With $94 Price Target
Solventum (SOLV) has an average rating of overweight and mean price target of $83, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$SOLV